Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Onconetix Inc (ONCO)

$3.07 -0.05 (-1.60%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	4.82M
Revenue (ttm)	2.52M
Net Income (ttm)	-58.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,328.97%
Debt to Equity Ratio	0.00

Volume	24,600
Avg Vol	698,030
Day's Range	N/A - N/A
Shares Out	1.55M
Stochastic %K	35%
Beta	3.39
Analysts	Strong Buy
Price Target	N/A

Company Profile

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, I...

Industry: Biotechnology

Sector: Healthcare

Phone: 513 620 4101

Website: www.onconetix.com

Address:

201 East Fifth Street, Suite 1900, Cincinnati, United States

trdrersin Oct. 6 at 6:28 PM

$ONCO

0 · Reply

Thespartantrade Oct. 6 at 5:03 PM

$JFBR $GCTK $CBIO $ONCO Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

Gainlock Oct. 6 at 1:45 PM

$ONCO Another no movement day I guess

0 · Reply

ReverseArb Oct. 5 at 3:41 PM

$ONCO Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.

0 · Reply

Schizoo Oct. 4 at 7:31 PM

$ONCO 🤌

0 · Reply

UnStopABULL Oct. 3 at 10:44 PM

$BOXL $BSLK $NVDA $ONCO $TSLA get into GIPR it’s running now!

0 · Reply

Vikingsstrade Oct. 3 at 7:31 PM

Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $ONCO $CHNR $CERO $ARTL

0 · Reply

Gainlock Oct. 3 at 2:36 PM

$ONCO Get in, will be running soon $BSLK $BOXL $NVDA $TSLA

0 · Reply

Gainlock Oct. 3 at 2:10 PM

$ONCO GOING UP $BTTC $MLGO $HOLO $GME

0 · Reply

trdrersin Oct. 3 at 1:52 PM

$ONCO waiting…

0 · Reply

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Sep 26, 2025, 8:15 AM EDT - 10 days ago

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Sep 22, 2025, 8:00 AM EDT - 14 days ago

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Jul 16, 2025, 8:17 AM EDT - 2 months ago

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Dec 12, 2024, 5:00 PM EST - 10 months ago

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

ENTO OCS VRNA

Oct 3, 2024, 4:45 PM EDT - 1 year ago

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 9:05 AM EDT - 1 year ago

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Crude Oil Rises; Onconetix Shares Spike Higher

Sep 27, 2024, 2:41 PM EDT - 1 year ago

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Dec 19, 2023, 7:00 AM EST - 1 year ago

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 18, 2023, 7:00 AM EST - 1 year ago

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Jul 31, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Jul 25, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Jul 17, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Jul 11, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Jul 6, 2023, 5:05 PM EDT - 2 years ago

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Jul 6, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Jun 21, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Jun 14, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

May 12, 2023, 6:32 PM EDT - 2 years ago

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 10, 2023, 12:15 PM EDT - 2 years ago

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

Apr 26, 2023, 3:44 PM EDT - 2 years ago

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Apr 24, 2023, 8:00 AM EDT - 2 years ago

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Apr 12, 2023, 8:30 AM EDT - 2 years ago

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine

Mar 9, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

Feb 6, 2023, 10:15 AM EST - 2 years ago

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

Feb 1, 2023, 9:15 AM EST - 2 years ago

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

Jan 17, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors

Jan 9, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

trdrersin Oct. 6 at 6:28 PM

$ONCO

0 · Reply

Thespartantrade Oct. 6 at 5:03 PM

0 · Reply

Gainlock Oct. 6 at 1:45 PM

$ONCO Another no movement day I guess

0 · Reply

ReverseArb Oct. 5 at 3:41 PM

$ONCO Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.

0 · Reply

Schizoo Oct. 4 at 7:31 PM

$ONCO 🤌

0 · Reply

UnStopABULL Oct. 3 at 10:44 PM

$BOXL $BSLK $NVDA $ONCO $TSLA get into GIPR it’s running now!

0 · Reply

Vikingsstrade Oct. 3 at 7:31 PM

0 · Reply

Gainlock Oct. 3 at 2:36 PM

$ONCO Get in, will be running soon $BSLK $BOXL $NVDA $TSLA

0 · Reply

Gainlock Oct. 3 at 2:10 PM

$ONCO GOING UP $BTTC $MLGO $HOLO $GME

0 · Reply

trdrersin Oct. 3 at 1:52 PM

$ONCO waiting…

0 · Reply

Gainlock Oct. 3 at 1:49 PM

$ONCO when will this piece of shit run? I’m running out of patience.

0 · Reply

MoonCowBoy Oct. 3 at 12:35 AM

$CBIO $ONCO $CHNR $CERO \

0 · Reply

Schizoo Oct. 2 at 3:41 PM

$ONCO balls n patience

0 · Reply

Gainlock Oct. 1 at 7:27 PM

$ONCO sad day

0 · Reply

Gainlock Oct. 1 at 4:34 PM

$ONCO stupid stock

0 · Reply

titto25 Oct. 1 at 10:37 AM

$ONCO when will merger take place

1 · Reply

Schizoo Sep. 30 at 7:20 PM

$ONCO

0 · Reply

Gainlock Sep. 30 at 3:47 PM

$ONCO it is sucking again 🤦🏽‍♂️

1 · Reply

Schizoo Sep. 30 at 2:56 PM

$ONCO 🤌🚀

0 · Reply

kancunbum Sep. 29 at 7:57 PM

$ONCO 💎🚀

0 · Reply

Gainlock Sep. 29 at 1:51 PM

$ONCO

0 · Reply

kancunbum Sep. 29 at 12:54 PM

$ONCO 💎

0 · Reply

1.0.0